Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
description
Transcript of Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
![Page 1: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/1.jpg)
Perspectives on PARP Inhibitors in Ovarian Cancer
Has the Time Come for Individualized Care?
![Page 2: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/2.jpg)
Activity Goals
![Page 3: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/3.jpg)
Epidemiology: Ovarian Cancer
![Page 4: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/4.jpg)
PARP and DNA Repair
![Page 5: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/5.jpg)
BRCA and DNA Repair
![Page 6: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/6.jpg)
Synthetic Lethality Is Associated With Inhibition of PARP in the Presence of BRCA Deficiency
![Page 7: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/7.jpg)
PARP Inhibition in BRCA-like Solid Tumors
![Page 8: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/8.jpg)
Repair Mechanisms and BRCAness
![Page 9: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/9.jpg)
BRCA Testing: When Should it Be Done?
![Page 10: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/10.jpg)
PARP Inhibition: Mechanism of Action
![Page 11: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/11.jpg)
Clinical Outcomes in Patients With BRCA Mutations
![Page 12: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/12.jpg)
PARP Inhibitors in Clinical Trials
![Page 13: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/13.jpg)
Case Study 1
![Page 14: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/14.jpg)
Treatment Options
![Page 15: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/15.jpg)
Anticipated PFS With Standard Treatment
![Page 16: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/16.jpg)
Olaparib as Maintenance Therapy: Study Design
![Page 17: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/17.jpg)
Results of BRCA Testing
![Page 18: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/18.jpg)
Results
![Page 19: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/19.jpg)
ASCO 2014: Cediranib/Olaparib
![Page 20: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/20.jpg)
PFS With Cediranib/Olaparib Superior to Olaparib Alone
![Page 21: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/21.jpg)
PFS Increased With Cediranib/Olaparib Combination
![Page 22: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/22.jpg)
Phase 2: PLD vs Olaparib
![Page 23: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/23.jpg)
Case Study 2
![Page 24: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/24.jpg)
Treatment Approach
![Page 25: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/25.jpg)
Neoadjuvant Chemotherapy (NACT) vs Primary Debulking
Surgery (PDS)
![Page 26: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/26.jpg)
Dose-Dense Paclitaxel + Carboplatin vs Conventional
Regimen
![Page 27: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/27.jpg)
![Page 28: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/28.jpg)
BRCAness and Response to Chemotherapy
![Page 29: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/29.jpg)
GOG9923
![Page 30: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/30.jpg)
Key Issues for Future Developments
of PARP Inhibitors
![Page 31: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/31.jpg)
Abbreviations
![Page 32: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/32.jpg)
References
![Page 33: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/33.jpg)
References (cont)
![Page 34: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/34.jpg)
References (cont)
![Page 35: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/35.jpg)
References (cont)
![Page 36: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/36.jpg)
References (cont)
![Page 37: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/37.jpg)
References (cont)
![Page 38: Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?](https://reader034.fdocuments.in/reader034/viewer/2022050723/56812d0a550346895d91ddad/html5/thumbnails/38.jpg)
References (cont)